^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
KUR-502
i
Other names: KUR-502, KUR-502 CAR-NKT Therapy, CD19.CAR-aNKT cells, CD19.CAR Allogeneic NKT, CMD-502, KUR502, KUR 502
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Athenex, Baylor College of Medicine, Texas Children’s Hospital
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
23d
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) (clinicaltrials.gov)
P1, N=13, Active, not recruiting, Baylor College of Medicine | Trial completion date: Feb 2035 --> May 2040 | Trial primary completion date: Jun 2026 --> Jun 2025
Trial completion date • Trial primary completion date
|
CD19 positive
|
cyclophosphamide • KUR-502
11ms
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) (clinicaltrials.gov)
P1, N=13, Active, not recruiting, Baylor College of Medicine | Trial primary completion date: Jun 2025 --> Jun 2026
Trial primary completion date
|
CD19 positive
|
cyclophosphamide • KUR-502
12ms
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) (clinicaltrials.gov)
P1, N=13, Active, not recruiting, Baylor College of Medicine | Trial completion date: Feb 2034 --> Feb 2035
Trial completion date
|
CD19 positive
|
cyclophosphamide • KUR-502
1year
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) (clinicaltrials.gov)
P1, N=13, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting | N=48 --> 13 | Trial completion date: Mar 2035 --> Feb 2034 | Trial primary completion date: Jan 2026 --> May 2025
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
CD19 positive
|
cyclophosphamide • KUR-502
almost2years
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) (clinicaltrials.gov)
P1, N=48, Recruiting, Baylor College of Medicine | Trial primary completion date: Apr 2025 --> Jan 2026
Trial primary completion date
|
cyclophosphamide • KUR-502
almost2years
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) (clinicaltrials.gov)
P1, N=48, Recruiting, Baylor College of Medicine | Trial primary completion date: Apr 2024 --> Apr 2025
Trial primary completion date
|
cyclophosphamide • KUR-502
3years
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) (clinicaltrials.gov)
P1, N=48, Recruiting, Baylor College of Medicine | Trial primary completion date: Apr 2023 --> Apr 2024
Trial primary completion date
|
CD19 positive
|
cyclophosphamide • KUR-502
over3years
ANCHOR2: Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies (clinicaltrials.gov)
P1, N=36, Recruiting, Athenex, Inc. | Not yet recruiting --> Recruiting
Enrollment open
|
CD19 (CD19 Molecule)
|
cyclophosphamide • KUR-502
almost4years
ANCHOR2: Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies (clinicaltrials.gov)
P1, N=36, Not yet recruiting, Athenex, Inc.
New P1 trial
|
CD19 (CD19 Molecule)
|
cyclophosphamide • KUR-502
over5years
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) (clinicaltrials.gov)
P1, N=48, Recruiting, Baylor College of Medicine | N=20 --> 48
Clinical • Enrollment change
|
CD19 (CD19 Molecule)
|
CD19 positive
|
fludarabine IV • KUR-502 • cyclophosphamide intravenous
Share via
